BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 16397046)

  • 1. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
    Kanao K; Mikami S; Mizuno R; Shinojima T; Murai M; Oya M
    J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
    Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
    Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells.
    Sakimura R; Tanaka K; Yamamoto S; Matsunobu T; Li X; Hanada M; Okada T; Nakamura T; Li Y; Iwamoto Y
    Clin Cancer Res; 2007 Jan; 13(1):275-82. PubMed ID: 17200366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
    Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
    Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
    Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
    J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
    Mitani Y; Oue N; Hamai Y; Aung PP; Matsumura S; Nakayama H; Kamata N; Yasui W
    J Pathol; 2005 Jan; 205(1):65-73. PubMed ID: 15586362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
    J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular responses in lung cancer patients receiving Romidepsin.
    Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Kruchin E; Wright JJ; Rosing DR; Sparreboom A; Figg WD; Steinberg SM
    Clin Cancer Res; 2008 Jan; 14(1):188-98. PubMed ID: 18172270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
    Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
    Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.
    Wang H; Zhou W; Zheng Z; Zhang P; Tu B; He Q; Zhu WG
    DNA Repair (Amst); 2012 Feb; 11(2):146-56. PubMed ID: 22112863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
    Kang J; Chen J; Shi Y; Jia J; Zhang Y
    Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
    Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
    Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.